GlassScriptPhysician profile
Michael P Stevens
NPI 1932198793
$21,122.48
in general payments reported to CMS, 2019-2025
25 companies · $562 in 2025
The $562 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $2,459 · 2021: $1,180 · 2022: $1,759 · 2023: $1,643 · 2024: $1,305 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,509.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $12,920.48 | 2019-2023 | |
| Janssen Biotech, INC. | $1,860.34 | 2019-2025 | Simponi Aria, Tremfya |
| Amgen INC. | $1,729.02 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Abbvie INC. | $1,126.55 | 2019-2025 | Rinvoq |
| Glaxosmithkline, LLC. | $738.54 | 2019-2024 | Benlysta |
| Novartis Pharmaceuticals Corporation | $685.08 | 2019-2025 | |
| Ucb, INC. | $618.90 | 2020-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $372.48 | 2021-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $236.90 | 2022-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $139.45 | 2019-2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| Lilly USA, LLC | $89.65 | 2022 | |
| Pfizer INC. | $87.20 | 2019-2025 | |
| Horizon Therapeutics Plc | $66.79 | 2020-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.93 | 2023 | Ofev |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $47.53 | 2022-2025 | Purified Cortrophin Gel |
| Hikma Pharmaceuticals USA | $38.85 | 2019 | |
| Organon LLC | $32.92 | 2025 | Renflexis, Hadlima |
| Takeda Pharmaceuticals U.S.A., INC. | $27.16 | 2020 | |
| Depuy Synthes Sales INC. | $27.12 | 2025 | Monovisc |
| Genentech USA, INC. | $22.98 | 2021 | |
| Daiichi Sankyo INC. | $19.28 | 2020 | |
| Scilex Pharmaceuticals INC. | $18.79 | 2024 | |
| Genzyme Corporation | $17.37 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $17.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.